Global Osteonecrosis Treatment Market - 2023-2030

Global Osteonecrosis Treatment Market - 2023-2030

Global Osteonecrosis Treatment Market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030 growing with a CAGR of YY% during the forecast period 2023-2030.

Osteonecrosis, also known as avascular necrosis or aseptic necrosis, is a medical condition that results in the death or necrosis of bone tissue due to a lack of blood flow. When blood flow to a certain bone is disturbed or limited, the bone cells deteriorate and eventually succumb.

The global osteonecrosis treatment market encompasses of various treatment such as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), cholesterol-lowering drugs, blood thinners. The market is driven by the factors such as increasing prevalence of osteonecrosis, excess use of steroids, traumatics injuries, increasing geriatric population and technological advancements.

Market Dynamics: Drivers and Restraints

The increasing number of alcohol consumption

The rising consumption of alcohol is one of the primary drivers of the osteonecrosis treatment market. Excessive alcohol use is an important risk factor for osteonecrosis because it inhibits blood circulation, reducing blood flow to bones, particularly weight-bearing joints like the hip and knee.

For instance, according to the National Library of Medicine 2023 article, alcohol intake is a major risk factor for osteonecrosis, affecting 20-45% of people with the disorder. Furthermore, the prevalence of aseptic necrosis in habitual drinkers was reported to be as high as 5.3%.

Furthermore, the rising prevalence of sickle cell anemia, a genetic blood disease characterized by malformed, sickle-shaped red blood cells that block small blood cells, restricting blood supply to organs including bones, may result in osteonecrosis. This decreased blood supply causes ischemia, which causes bone tissue cells to die due to a lack of oxygen and nutrients. For instance, according to a National Library of Medicine 2022 article, osteonecrosis of the femoral head has been described to be 22% in patients with sickle cell disease and up to 50%.

Moreover, other factors such as increasing number of steriod use, increasing prevalence of systemic lupus erythematosus, gaucher disease and kidney transplantation are expected to drive the market over the forecast period.

Market Dynamics: Restraint

The high cost assoicated with the available treatments, risk factors associated with treatment drugs. Moreover, the limited awareness of disease symptoms, and a scarcity of treatment options for advanced stages, often necessitating joint replacement surgery. Thus, restraining the osteonecrosis treatment market over the foreseenable period.

Segment Analysis

The global osteonecrosis treatment market is segmented based on type, treatment, sales channel and region.

The surgery segment accounted for approximately 51.2% of the osteonecrosis treatment market share

The treatment segment in which surgery total joint replacement segment is expected to dominate the market. The total joint replacement is the treatment of choice in late-stage osteonecrosis when the joint is destroyed. In this surgery, the diseased joint is replaced with artificial parts. It may be recommended for people who are not good candidates for other treatments, such as patients who do not do well with repeated attempts to preserve the joint.

For instance, in February 2021, the U.S. Food and Drug Administration (FDA) approved the Patient Specific Talus Spacer 3D-printed talus implant for humanitarian use. The Patient Specific Talus Spacer is the first-of-its-kind implant to replace the talus—the bone in the ankle joint that connects the leg and foot—for the treatment of AVN of the ankle joint. Thus, owing to the above factors the segment is expected to dominate over the forecast period.

Geographical Penetration

North America accounted for approximately 37.4% of the market share in 2022

The North America region particulary the U.S. is expected to dominate the market owing to the factors such as increasing prevalence of osteonecrosis, increasing number of clinical trial, and presence of key market players in this region

For instance, according to National Organization for Rare Disorders 2021 article, in U.S. osteonecrosis is particularly seen in people aging around 30 to 50 years of age that accounts about 10,000 to 20,000 people suffering from osteonecrosis in this country.

Furthermore, in May 2022, Regrow Biosciences has received approval from the USFDA to begin a phase II study of its lead product 'OSSGROW,' an orphan medicine that aids in the effective treatment of Osteonecrosis, in the US market. Regrow Biosciences has received an Orphan Drug Designation (ODD) from the USFDA and EMA for OSSGROW. Thus, owing to the above factors the region is expected to dominate over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has had significant effects on the osteonecrosis treatment market, owing to the widespread usage of steroids in COVID-19 patient care. Steroid therapy during the early stages of COVID-19 resulted in a significant increase in the incidence of avascular necrosis (AVN) among patients. As a result, there was an increase in demand for osteonecrosis treatment alternatives, such as pharmacological treatments and surgical operations. This increased demand put further strain on healthcare infrastructure, with hospitals having to choose between COVID-19 and AVN patients. However, the situation offered chances for research and development, promoting the study of novel AVN therapy.

Regional differences in AVN cases emerged, as evidenced by India's Apollo Hospitals, which treated a large number of AVN patients. As the healthcare sector adjusts to the post-pandemic landscape, vigilance, responsiveness to changing patient needs, and ongoing research in osteonecrosis treatment remain critical, while public health guidelines should be continually refined to reduce future treatment-related complications in healthcare crises.

Competitive Landscape

The major global players in the osteonecrosis treatment market include Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Mylan N.V., Zimmer Biomet, Stryker, Merck & Co.,Inc, Horizon Therapeutics plc, Biotek., Upsher-Smith Laboratories, LLC, and among others.

Key Developments
• On February 17, 2021, The Patient Specific Talus Spacer 3D-printed talus implant has been approved for humanitarian use by the US Food and Drug Administration. The Patient Specific Talus Spacer is a first-of-its-kind implant that replaces the talus—the bone in the ankle joint that connects the leg and the foot—for the treatment of avascular necrosis (AVN) of the ankle joint, a serious and progressive condition that causes bone tissue death due to a lack of blood supply to the area.

Why Purchase the Report?
• To visualize the global osteonecrosis treatment market segmentation based on type, treatment, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of osteonecrosis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global osteonecrosis treatment market report would provide approximately 61 tables, 54 figures and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies